18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and mouse studies suggest T cell-specific inhibition of XBP1 or IRE1 could help treat ovarian cancer. In tumor and ascites samples from patients, high T cell expression of XBP1 was...
18:19 , Oct 18, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays, diagnostic assays; plasma markers Circulating CD4+ T cells specific for full-length C-peptide could be used for early diagnosis of Type I diabetes. In peripheral blood samples from patients with recent-onset Type I diabetes,...
17:37 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD); organ transplant rejection; renal transplant rejection Mouse and non-human primate studies suggest inhibiting CD122 could enhance the efficacy of Nulojix belatacept to treat GvHD, skin graft rejection and renal transplant rejection. In...
19:27 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; other

TECHNOLOGY: Cellular assays; computational models An algorithm based on cytometric data from multiple studies could help identify cell populations as diagnostic or prognostic markers of disease. The algorithm involves three steps. First, it processes raw...
17:56 , Aug 29, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays An epigenetic-based method of quantifying blood cell types could aid the differential diagnosis of immunodeficiencies such as severe combined immunodeficiency (SCID). The method involves four steps: treating DNA isolated from patient blood samples...
02:36 , Aug 24, 2018 |  BC Innovations  |  Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
15:54 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious

INDICATION: HIV/AIDS Primate studies suggest combining CD4 mimetics with HIV gp120-based vaccines could help prevent HIV. In macaques challenged with simian human immunodeficiency virus (SHIV) immunized with HIV gp120 variants, a CD4 mimetic prevented infection in...
16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis; multiple sclerosis (MS) Cell culture and mouse studies suggest inhibiting autophagy in T cells could treat juvenile idiopathic arthritis (JIA), MS and other autoimmune diseases. In activated primary CD4+ T cells from the synovial...
23:52 , Aug 8, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Cell culture studies suggest inhibiting L selectin shedding could help treat latent HIV infection. In L selectin-expressing CD4+ T cells exposed to HIV-1, a tool compound matrix metalloproteinase 1 (MMP1) inhibitor that blocks...
16:56 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection

Merck & Co. Inc. (NYSE:MRK) said once-daily oral doravirine (MK-1439) in combination with other antiretroviral therapies (ARTs) led to viral suppression at week 96 in 73.1% of patients vs. 66% of patients treated with ritonavir-boosted...